Clinical trial · Interventional
Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy
A Feasibility Study of Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapies
NCT03177317CI-TRIAL-00048580completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Feasibility study to evaluate the efficacy of reduced prophylactic dose of dexamethasone in elderly patients receiving moderate emetogenic chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Elderly patients (>= 70 years of age)
- description
- Dexamethasone 8mg intravenously before chemotherapy
- interventionNames
- Drug: Dexamethasone
Primary outcomes (1)
- measure
- Complete response (CR)
- timeFrame
- 2 weeks
- description
- No emetic episode, no rescue medicine
Secondary outcomes (2)
- measure
- Complete control (CC)
- timeFrame
- 2 weeks
- description
- complete response with no more than mild nausea
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed colorectal cancer patients with curative resection * ECOG performance status 0-2 * Provision of signed, written and dated informed consent prior to any study specific procedures * Receiving adjuvant chemotherapy with FOLFOX (5-FU, leucovorin, oxaliplatin) regimen Exclusion Criteria: * Having contraindication to dexamethasone * Having nausea or vomiting before the start of adjuvant chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.